It’s the leading cause of cancer death in the United States – and it’s treatable: lung cancer kills some 127,000 people annually in the U.S., but it’s not a hopeless disease, and in fact, can often be treated if detected early.
While treatments continue to improve with breakthrough “targeted” therapies, it’s early detection that could prevent enormous numbers of lung cancer deaths. But screening rates for lung cancers remain significantly lower than for other cancers, and according to a new Stanford Medicine study, they’re disproportionally failing minority populations, including African Americans.
What’s the key to beating lung cancer in the U.S. and around the world? What are the racial disparities in lung cancer detection and treatment, and how can these disparities be addressed?
For Lung Cancer Awareness and National Smoking Cessation Month, we welcome two Ohio-based global leaders in lung cancer research to unpack the causes, examine groundbreaking detection strategies for – and new targeted treatments of – America’s number one cancer killer. Featuring David P. Carbone, MD, PhD, Barbara J. Bonner Chair in Lung Cancer Research, Director, James Thoracic Center, and Co-Leader, Translational Therapeutics Program, The Ohio State University Comprehensive Cancer Center, and Jasleen Pannu, MMBS, Director of Interventional Pulmonary Translational Research, and Assistant Professor, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University Wexner Medical Center, with Cierra Johnson, Anchor and Reporter, WCMH NBC4.
